Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-03
Description
This notice is for the conclusion of agreements with pharmaceutical companies in accordance with Section 130a (8) sentence 1 SGB V. The invitation to participate is addressed only to pharmaceutical companies or associations of pharmaceutical companies as defined in Section 4 (18) of the Medicinal Products Act. This is not an Open Procedure in accordance with Section 15 of the VgV in conjunction with Section 119 (3) of the GWB, but a publication of the invitation to conclude/join discount contracts with conditions fixed and non-negotiable for all participants, including the level of the discount. An unlimited number of pharmaceutical companies or associations of pharmaceutical companies as defined in Section 4 (18) of the Medicinal Products Act may become contracting parties.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ponesimod, ATC L04AE04
AOK Rheinland-Pfalz/Saarland - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 710 daysPublished on Sep 20, 2026
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ebastin, ATC R06AX22
AOK Rheinland-Pfalz/Saarland - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 710 daysPublished on Sep 20, 2026
Germany – Devices and instruments for infusion – Infusionstechnik Klinikum Oldenburg
Klinikum Oldenburg AöRGermanyDevices and instruments for infusionDeadline in 28 daysPublished on Sep 20, 2026
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Vaginalring mit Gestagenen und Estrogenen, ATC G02BB01
AOK Rheinland-Pfalz/Saarland - Die GesundheitskasseGermanyPharmaceutical productsDeadline in 710 daysPublished on Sep 20, 2026